Form D · Biotechnology

TALIGEN THERAPEUTICS INC

Cambridge, MA · CIK 0001337769

Offering snapshot reported Sep 2, 2010 · SEC filing

Reported sold
$36M
Offering amount: $65M
Investors reported
10
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 3, 2008
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$18M$36MMay 11, 2009: $26,048,897.00May 11, 2009Sep 2, 2010: $36,048,893.00Sep 2, 2010

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$26,048,897 → $36,048,893

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 2, 2010Amendment$36,048,893$9,999,996vs May 11, 200910SEC filing
May 11, 2009Amendment$26,048,897No comparisonNot reportedSEC filing
Jan 17, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Aug 31, 2005PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-80731

Source: Form D, filed Sep 2, 2010. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Abbie Celniker Director, Executive
Nicholas Galakatos Director
Ed Hurwitz Director
John Maraganore Director
Timothy C Mills Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
245 First Street Suite 1100
Cambridge, MA, 02142